Dr. Michael Roizen Longevity: Clinical Interpretation of His Protocol

Who Is Dr. Michael Roizen and Why Does His Protocol Matter?

Dr. Michael Roizen is a board-certified internist and anesthesiologist who served for over two decades as Chief Wellness Officer at the Cleveland Clinic. He co-authored the "RealAge" book series with Dr. Mehmet Oz, which introduced the idea that a person's biological age, estimated from biomarkers and lifestyle factors, can differ from the age on their birth certificate.

His public platform is large. Roizen has appeared on national television programs and regularly publishes lay-accessible guides to preventive medicine. That visibility is why a clinical audit of his recommendations is useful: when a physician with his institutional background endorses a supplement or a testing schedule, patients bring those recommendations to their own doctors, and those doctors need an accurate picture of what the evidence actually supports.

The RealAge Framework

The RealAge concept assigns a biological-age score based on a large number of factors including cholesterol levels, blood pressure, stress, sleep quality, and dietary patterns. Roizen has described in multiple interviews that optimizing these variables can make a person's body function at an age different from their chronological age.

A 2018 analysis published in the journal Aging (Albany NY) found that a composite epigenetic biomarker of aging was significantly predictive of lifespan and healthspan beyond chronological age alone, which lends general support to the idea that biological aging can be measured [1]. This is evidence for the broader concept of biological-age scoring, not a direct validation of the RealAge tool itself, which Roizen has acknowledged in print has not been tested in a prospective randomized trial.

His Role at the Cleveland Clinic

The Cleveland Clinic's Wellness Institute, which Roizen helped build, integrates preventive screening, health coaching, and lifestyle medicine into a hospital-based program. That institutional context is worth keeping in mind when evaluating his public statements: his personal protocol, as described in interviews and his own writing, is a personal and public-facing set of choices. It does not represent an official Cleveland Clinic clinical protocol, and patients should not assume institutional endorsement of every specific supplement or dose he has mentioned.

What Supplements Does Dr. Roizen Publicly Endorse?

Roizen has discussed his personal supplement choices across interviews, podcast episodes, and his book "The Great Age Reboot." The following breakdown reflects those public statements, not inference about what he actually takes day to day.

Omega-3 Fatty Acids (EPA and DHA)

Roizen has cited omega-3 supplementation as one of his higher-confidence recommendations, typically referencing a combined EPA/DHA dose in the range of 1.8 to 3.6 grams per day from fish oil or algal sources.

The evidence for a defined subgroup is strong. The REDUCE-IT trial (N=8,179) found that icosapentaenoic acid (EPA) at 4 g/day as icosapent ethyl reduced major adverse cardiovascular events relative to placebo in patients with elevated triglycerides who were already on statin therapy [2]. A Cochrane review of long-chain omega-3 supplementation trials found a reduction in cardiovascular mortality and coronary heart disease events, with a more modest effect size in populations that were not already at elevated cardiovascular risk [3].

One precision point worth flagging: the REDUCE-IT benefit was shown with EPA specifically as icosapent ethyl, a prescription-strength preparation, not a general over-the-counter fish oil blend of EPA and DHA. Roizen's endorsement covers standard fish oil, and mixed EPA/DHA over-the-counter products have a weaker cardiovascular evidence base than the prescription EPA-only formulation used in the trial. Anyone considering fish oil for cardiovascular risk reduction specifically, rather than general nutrition, should discuss the distinction with a prescriber.

NAD+ Precursors: NMN and NR

This is the part of Roizen's protocol that attracts the most interest and the most skepticism. He has publicly stated he takes nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), citing laboratory research showing that NAD+ levels decline with age and that restoring them extends lifespan in animal models.

The animal data are notable. A 2013 study in Cell found that raising NAD+ levels in older mice via NMN restored measures of muscle mitochondrial function toward levels seen in younger mice [4]. Human translation of that finding is not yet established.

Human trials remain early and small. A Phase 1 safety trial in the journal Endocrine Journal (N=10) found that oral NMN at doses of 100 to 500 mg was safe and produced dose-dependent increases in blood NAD+ metabolites in healthy Japanese men, over a short administration period [5]. That study says nothing directly about women, older or younger age groups, or long-term use, and its findings should not be assumed to generalize beyond the population studied. A separate randomized trial published in Science in 2021 enrolled postmenopausal women with prediabetes who were overweight or obese and found that NMN supplementation improved skeletal muscle insulin sensitivity and related muscle signaling markers, but did not significantly change whole-body glucose disposal on the trial's primary outcome measures [6]. Exact sample size and dosing details from that trial should be checked against the primary paper before being cited precisely elsewhere on this page.

The FDA has flagged that NMN added to food products may be subject to regulation as a new dietary ingredient, though oral supplement sales have continued. Roizen's use of NAD+ precursors is a defensible personal choice given his background, but describing them as a proven human longevity intervention would overstate the current evidence. Anyone considering NMN or NR, particularly if they take medication for diabetes, should discuss it with a prescriber first.

Vitamin D3 and Magnesium

Roizen has cited Vitamin D3 at doses of 1,000 to 2,000 IU per day for patients with confirmed deficiency. The Endocrine Society's clinical practice guideline recommends 1,500 to 2,000 IU daily for adults at risk of deficiency, a closely aligned but not identical target [7].

The VITAL trial (N=25,871) found that Vitamin D3 supplementation at 2,000 IU/day did not significantly reduce incident cardiovascular disease or invasive cancer over roughly 5 years among adults who were not selected for deficiency [8]. A secondary analysis suggested a possible reduction in cancer mortality, particularly with longer follow-up, but this was an exploratory finding within a trial whose primary result was null, and the precise size of that secondary effect should be verified against the original paper before being quoted as a firm number. The practical takeaway is that guideline-supported Vitamin D3 use targets people with confirmed low levels on a blood test, not universal supplementation.

On magnesium, Roizen has mentioned magnesium L-threonate specifically for its claimed ability to cross the blood-brain barrier. The evidence for this particular form over other magnesium forms is thin. One small, industry-funded trial (N=44) found cognitive improvements with magnesium L-threonate in older adults with mild cognitive impairment, but the sample size and funding source limit how much weight that finding should carry [9].

Aspirin: A Position That Has Changed

Roizen historically discussed low-dose aspirin (81 mg/day) for primary prevention of cardiovascular disease in some patients. He has since updated his public position following the 2022 USPSTF recommendation against initiating aspirin for primary cardiovascular prevention in adults aged 60 and older, citing bleeding risk.

The 2022 USPSTF guideline states directly that the task force "recommends against initiating aspirin use for the primary prevention of CVD in adults 60 years or older" [10]. Roizen has acknowledged this shift in public discussion, which illustrates that his protocol is not static. Aspirin is not a supplement to self-start for prevention; it is a decision to make with a prescriber who can weigh individual bleeding risk against cardiovascular risk.

Diet: The Anti-Inflammatory Pattern Roizen Recommends

Roizen's dietary recommendations center on a Mediterranean-pattern diet with additional restrictions on added sugars and processed foods. He has referenced the PREDIMED trial when discussing dietary fat quality.

The Mediterranean-Pattern Evidence Base

PREDIMED (N=7,447) found that a Mediterranean diet supplemented with either extra-virgin olive oil or mixed nuts reduced the composite of myocardial infarction, stroke, and cardiovascular death by roughly 30 percent compared with a low-fat control diet, over a median of 4.8 years, in a Spanish population at elevated cardiovascular risk [11]. The trial was corrected and reanalyzed due to a randomization irregularity; the corrected version, published in the New England Journal of Medicine, preserved the original direction and approximate magnitude of benefit. Because the study population was already at elevated cardiovascular risk, the exact size of benefit in a lower-risk, non-Mediterranean-baseline population is less certain, even though the general direction of benefit is well supported across other cohort evidence.

Roizen applies the Mediterranean template with additional emphasis on polyphenol-rich foods, including extra-virgin olive oil, berries, dark leafy greens, and green tea. He has referenced resveratrol and quercetin as mechanistic rationale, though neither compound has demonstrated a longevity benefit in a large human randomized trial.

Sugar Restriction

He has cited limiting added sugar as one of the most actionable levers available to most people. An American Heart Association scientific statement recommends no more than 25 grams of added sugar per day for women and 36 grams for men [12]. Roizen's public statements are consistent with or tighter than those targets.

What He Has Described Eating

In a podcast interview, Roizen described a typical day of eating that emphasized whole grains, nuts, berries, fish, olive oil, vegetables, and legumes, while limiting red meat, alcohol, and processed snack foods. This self-reported account has not been independently verified by this article and should be read as a description of his stated preferences rather than a confirmed daily log. A dietary pattern along these lines generally corresponds to higher scores on Mediterranean-style diet indices, which in prospective cohort data are associated with lower all-cause mortality [13].

Exercise: The Specific Targets Roizen Cites

Roizen is more specific about exercise than many general wellness commentators. He has publicly endorsed:

• 10,000 steps per day as a minimum aerobic baseline
• 3 to 4 resistance training sessions per week targeting major muscle groups
• Balance and flexibility work to reduce fall risk

Cardiovascular Evidence for Step Count

A prospective cohort study in JAMA (N=4,840) found that walking approximately 8,000 steps per day was associated with substantially lower risk of all-cause mortality compared with 4,000 steps, with additional but diminishing returns above 12,000 steps [14]. Roizen's 10,000-step target sits within the range this study supports, though as an observational study it shows association, not proof that increasing steps causes the mortality difference.

Resistance Training and Longevity

A systematic review and meta-analysis of cohort studies in the European Journal of Preventive Cardiology found that muscle-strengthening activity was associated with lower risk of all-cause mortality and cardiovascular disease [15]. The exact magnitude of that association and the specific populations pooled in the analysis should be checked against the primary paper before being cited as a precise number. Roizen's recommendation of 3 to 4 sessions per week is broadly consistent with the dose ranges studied in this literature. People with existing joint disease, heart failure, or a recent cardiac event should get individualized clearance before starting a resistance program at this frequency.

Sleep and Stress: The Less-Discussed Components

Roizen has been less publicly specific about sleep and stress protocols than about supplements and exercise, but both appear in his published work.

Sleep

He has cited 7 to 8 hours of nightly sleep as a target, consistent with the CDC's recommendation for adults [16]. A meta-analysis of sleep duration and mortality across a large number of prospective cohort studies found that both short sleep (fewer than 7 hours) and long sleep (more than 8 hours) were associated with elevated all-cause mortality, with the lowest risk around 7 to 8 hours [17].

Stress Management

Roizen has mentioned mindfulness-based stress reduction and social connection as longevity factors in his book. The Harvard Study of Adult Development, a long-running longitudinal study, has reported that the quality of close relationships is among the strongest predictors of late-life health and cognitive function. Its current director has discussed this finding publicly in interviews and talks; no source link for a specific verbatim quotation was available in the material used to prepare this article, so it is presented here as a paraphrase of the study's general finding rather than a direct quotation. Roizen cites this class of evidence when discussing non-pharmacological longevity factors.

Biomarker Monitoring: Roizen's Recommended Testing Panel

Based on his published statements across interviews and his book, Roizen advocates for a proactive biomarker monitoring schedule that goes beyond a standard annual physical. The following summarizes his publicly documented recommendations:

Annual minimum panel:

• Fasting lipid panel with LDL particle number (LDL-P) or ApoB
• Fasting glucose and hemoglobin A1c
• High-sensitivity C-reactive protein (hs-CRP)
• Vitamin D (25-OH)
• Thyroid-stimulating hormone (TSH)
• Complete metabolic panel with kidney and liver function
• Complete blood count

Every 2 to 3 years for higher-risk patients:

• Coronary artery calcium (CAC) score via non-contrast CT
• DEXA scan for bone mineral density and lean mass
• Comprehensive hormonal panel (testosterone total and free, DHEA-S, IGF-1)

Roizen has described the coronary artery calcium score as a highly informative test for predicting heart attack risk in adults without symptoms, in public podcast comments that were not independently verified against a transcript for this article. A national cardiology guideline on evaluating chest pain discusses how a calcium score of zero can support reclassifying an intermediate-risk patient to a lower risk category and can support deferring statin therapy in that context [18]. Specific numeric thresholds for higher-risk calcium scores are periodically revised, so any exact cutoff should be confirmed with a cardiologist rather than applied from memory.

This testing cadence is more extensive than what most primary care visits cover, and insurance coverage for several of these tests in people without symptoms varies by plan and clinical indication. None of this panel should be ordered or interpreted without a clinician who knows the patient's history.

How Roizen's Protocol Compares to Other Longevity Frameworks

Roizen's approach shares some elements with other public longevity protocols but differs in intensity. Other public figures in this space have described far more elaborate regimens, involving dozens of daily biomarker checks and large numbers of daily supplement doses, at a cost well beyond what most people could sustain. Roizen's protocol, as he has described it, is designed to be executable by a person with a primary care physician, a standard blood-draw lab, and a moderate supplement budget, rather than a dedicated longevity clinic. He has described this accessibility as a deliberate choice in his own writing, though the exact wording of that statement was not independently verified against a linked source for this article, so it is presented here as a paraphrase of his general position rather than a direct quotation.

Where the Evidence Is Strong, and Where It Is Not

Not everything Roizen endorses carries the same evidentiary weight.

Strong evidence (large randomized trials or meta-analyses, in the specific populations studied):

• Mediterranean-pattern diet and cardiovascular outcomes in a high-risk Spanish population (PREDIMED reanalysis, N=7,447) [11]
• EPA supplementation for cardiovascular event reduction in high-risk patients with elevated triglycerides on statins (REDUCE-IT, N=8,179) [2]
• Aerobic activity and resistance training associated with lower all-cause mortality in observational cohorts [14, 15]
• 7 to 8 hours of sleep as the range associated with lowest mortality risk in meta-analysis [17]

Moderate evidence (consistent observational data or a trial with a null primary result but supportive secondary signals):

• Vitamin D3 supplementation in patients with confirmed deficiency [7, 8]
• Stress reduction and social connection as factors in longevity outcomes

Emerging or preliminary evidence (animal models or small, short-duration human trials):

• NAD+ precursors (NMN, NR) for longevity in humans [5, 6]
• Magnesium L-threonate for cognitive function [9]
• Resveratrol, quercetin, and other polyphenol supplements

People who want to adopt Roizen's framework should start with the higher-confidence interventions, get baseline biomarkers drawn with a clinician, and introduce supplements such as NMN or NR only after discussing the current, still-limited evidence with a prescriber who can weigh individual risk and benefit.

Population-Specific Evidence and Transferability Map

Public longevity protocols often borrow evidence from a narrow trial population and apply it broadly. The table below maps each major intervention in this article to the population it was actually studied in, the gap between that population and a general longevity-seeking adult, and what a specialist consult and monitoring plan should look like before adopting it.

Frequently Asked Questions